The Clinical Efficacy of N-Acetylcysteine in the Treatment of ST Segment Elevation Myocardial Infarction A Meta-Analysis and Systematic Review
The aim of this study was to evaluate the clinical efficacy of N-acetylcysteine (NAC) in the treatment of ST segment elevation myocardial infarction (STEMI).PubMed, EMBASE, Cochrane Library, and Web of Science were searched systematically from the establishment of the database to June 2020. Two rese...
Saved in:
Published in | International Heart Journal Vol. 62; no. 1; pp. 142 - 147 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Tokyo
International Heart Journal Association
30.01.2021
Japan Science and Technology Agency |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The aim of this study was to evaluate the clinical efficacy of N-acetylcysteine (NAC) in the treatment of ST segment elevation myocardial infarction (STEMI).PubMed, EMBASE, Cochrane Library, and Web of Science were searched systematically from the establishment of the database to June 2020. Two researchers independently completed literature screening and data extraction and conducted a meta-analysis.Nine articles including 1419 patients were enrolled. Meta-analysis showed that all-cause mortality [RR = 0.56, 95%CI (0.33, 0.93), P = 0.02], occurrence of major adverse cardiovascular events (MACE) [RR = 0.63, 95%CI (0.47, 0.85), P = 0.002], and myocardial enzyme hs-TnT level [SMD = -0.42, 95%CI (-0.71, -0.13), P = 0.005] were significantly lower in patients with STEMI treated with NAC than those in the control group. There was no significant difference between the NAC group and the control group in new congestive heart failure [RR = 0.94, 95%CI (0.48, 1.82), P = 0.84], ejection fraction [MD = 2.00, 95%CI (-0.59, 4.60), P = 0.13], and CK-MB [SMD = -0.18, 95%CI (-0.47, 0.11), P = 0.23]. There was no significant difference in the occurrence of adverse reactions between the NAC group and the control group [RR = 1.04, 95%CI (0.57-1.89), P = 0.90].NAC can reduce the all-cause mortality and MACE cases of STEMI. |
---|---|
AbstractList | The aim of this study was to evaluate the clinical efficacy of N-acetylcysteine (NAC) in the treatment of ST segment elevation myocardial infarction (STEMI).PubMed, EMBASE, Cochrane Library, and Web of Science were searched systematically from the establishment of the database to June 2020. Two researchers independently completed literature screening and data extraction and conducted a meta-analysis.Nine articles including 1419 patients were enrolled. Meta-analysis showed that all-cause mortality [RR = 0.56, 95%CI (0.33, 0.93), P = 0.02], occurrence of major adverse cardiovascular events (MACE) [RR = 0.63, 95%CI (0.47, 0.85), P = 0.002], and myocardial enzyme hs-TnT level [SMD = -0.42, 95%CI (-0.71, -0.13), P = 0.005] were significantly lower in patients with STEMI treated with NAC than those in the control group. There was no significant difference between the NAC group and the control group in new congestive heart failure [RR = 0.94, 95%CI (0.48, 1.82), P = 0.84], ejection fraction [MD = 2.00, 95%CI (-0.59, 4.60), P = 0.13], and CK-MB [SMD = -0.18, 95%CI (-0.47, 0.11), P = 0.23]. There was no significant difference in the occurrence of adverse reactions between the NAC group and the control group [RR = 1.04, 95%CI (0.57-1.89), P = 0.90].NAC can reduce the all-cause mortality and MACE cases of STEMI. |
Author | Jiang, Shi-Jun Huang, Cheng-Hu |
Author_xml | – sequence: 1 fullname: Jiang, Shi-Jun organization: School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology – sequence: 2 fullname: Huang, Cheng-Hu organization: Department of Endocrinology, Affiliated Taihe Hospital of Hubei University of Medicine |
BookMark | eNo9kF1PwjAUhhuDiYDe-AuWeGcybNd1W-8kBJUE9QK8brrulHUZHXbFZP_eDQg35_M570neCRrZxgJCjwTPCKPJiymrWYRDRvgNGhMa85BGnI8udUQTdocmbVthHBOG0zEqtyUEi9pYo2QdLLXus-qCRgdf4VyB72rVtR6MhcDYwPfw1oH0e7B-gDbbYAO7U7es4U9609jgs2uUdIXpBVdWS6eG6T261bJu4eGSp-jnbbldfITr7_fVYr4OFWWJD1We5yrRBc44ySgUqWZYMy6BFxlEKucQ4YzkmHCCkzjPFI51ESvFMSEpl4xO0dNZ9-Ca3yO0XlTN0dn-pYjiLCEsTlPaU89nSrmmbR1ocXBmL10nCBaDk6J3UkRY9E728OsZrlovd3BFpfNG1XBCk0iQIZxPritVSifA0n8pPn_C |
Cites_doi | 10.1001/jama.2018.5281 10.1097/MJT.0000000000000309 10.1016/S0049-3848(03)00284-6 10.1016/S0140-6736(05)61514-0 10.1073/pnas.84.5.1404 10.1056/NEJM198010163031601 10.1093/eurheartj/ehu299 10.1161/CIRCULATIONAHA.113.004046 10.1254/jphs.FP0071664 10.1016/0891-5849(95)00077-B 10.1186/1475-2840-10-43 10.3390/molecules23123305 10.1161/CIRCULATIONAHA.117.027575 10.1056/NEJMoa054209 10.1046/j.1365-2362.2001.00815.x 10.1016/S0002-9149(96)90580-9 10.1056/NEJM198709243171304 10.1093/eurheartj/ehm003 10.1056/NEJMra071667 10.1161/01.CIR.56.5.786 10.1161/01.CIR.68.6.1247 10.1161/CIR.0b013e3182285a81 10.1161/01.CIR.77.4.787 10.1016/j.jcin.2018.05.052 10.1007/s40256-013-0048-x 10.1161/CIRCINTERVENTIONS.113.000653 10.1253/circj.70.832 10.1016/j.jacc.2009.08.091 10.1007/s40256-017-0258-8 10.1007/s001010050270 10.1007/s40268-013-0025-5 |
ContentType | Journal Article |
Copyright | 2021 by the International Heart Journal Association Copyright Japan Science and Technology Agency 2021 |
Copyright_xml | – notice: 2021 by the International Heart Journal Association – notice: Copyright Japan Science and Technology Agency 2021 |
DBID | AAYXX CITATION 7QP |
DOI | 10.1536/ihj.20-519 |
DatabaseName | CrossRef Calcium & Calcified Tissue Abstracts |
DatabaseTitle | CrossRef Calcium & Calcified Tissue Abstracts |
DatabaseTitleList | Calcium & Calcified Tissue Abstracts |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1349-3299 |
EndPage | 147 |
ExternalDocumentID | 10_1536_ihj_20_519 article_ihj_62_1_62_20_519_article_char_en |
GroupedDBID | --- .55 29J 2WC 53G 5GY ACPRK ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS BAWUL CS3 DIK DU5 E3Z EBS EJD F5P GX1 JSF JSH KQ8 OK1 RJT RZJ SDH TR2 X7M AAYXX CITATION 7QP |
ID | FETCH-LOGICAL-c356t-cbbbc6fd089183ed7f50f59ae9d8e2cb9e2081b0191064b8c04fd4cc901179a53 |
ISSN | 1349-2365 |
IngestDate | Thu Oct 10 15:45:16 EDT 2024 Fri Aug 23 03:31:33 EDT 2024 Wed Apr 05 07:44:14 EDT 2023 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c356t-cbbbc6fd089183ed7f50f59ae9d8e2cb9e2081b0191064b8c04fd4cc901179a53 |
OpenAccessLink | https://www.jstage.jst.go.jp/article/ihj/62/1/62_20-519/_article/-char/en |
PQID | 2486154773 |
PQPubID | 2048496 |
PageCount | 6 |
ParticipantIDs | proquest_journals_2486154773 crossref_primary_10_1536_ihj_20_519 jstage_primary_article_ihj_62_1_62_20_519_article_char_en |
PublicationCentury | 2000 |
PublicationDate | 2021/01/30 |
PublicationDateYYYYMMDD | 2021-01-30 |
PublicationDate_xml | – month: 01 year: 2021 text: 2021/01/30 day: 30 |
PublicationDecade | 2020 |
PublicationPlace | Tokyo |
PublicationPlace_xml | – name: Tokyo |
PublicationTitle | International Heart Journal |
PublicationTitleAlternate | Int. Heart J. |
PublicationYear | 2021 |
Publisher | International Heart Journal Association Japan Science and Technology Agency |
Publisher_xml | – name: International Heart Journal Association – name: Japan Science and Technology Agency |
References | 27. Anfossi G, Russo I, Massucco P, Mattiello L, Trovati M. Platelet resistance to the antiaggregating effect of N-acetyl-L-cysteine in obese, insulin-resistant subjects. Thromb Res 2003; 110: 39-46. 10. Nozari Y, Eshraghi A, Talasaz AH, et al. Protection from reperfusion injury with intracoronary N-acetylcysteine in patients with STEMI undergoing primary percutaneous coronary intervention in a Cardiac Tertiary Center. Am J Cardiovasc Drugs 2018; 18: 213-21. 14. Tanaka A, Suzuki Y, Suzuki N, et al. Does N-acetylcysteine reduce the incidence of contrast-induced nephropathy and clinical events in patients undergoing primary angioplasty for acute myocardial infarction? Intern Med 2011; 50: 673-7. 24. Tsujita K, Shimomura H, Kaikita K, et al. Long-term efficacy of edaravone in patients with acute myocardial infarction. Circ J 2006; 70: 832-7. 12. Talasaz AH, Khalili H, Jenab Y, Salarifar M, Broumand MA, Darabi F. N-Acetylcysteine effects on transforming growth factor-β and tumor necrosis factor-α serum levels as pro-fibrotic and inflammatory biomarkers in patients following ST-segment elevation myocardial infarction. Version 2. Drugs R D 2013; 13: 199-205. 23. Grech ED, Dodd NJ, Jackson MJ, Morrison WL, Faragher EB, Ramsdale DR. Evidence for free radical generation after primary percutaneous transluminal coronary angioplasty recanalization in acute myocardial infarction. Am J Cardiol 1996; 77: 122-7. 26. Spies C, Giese C, Meier-Hellmann A, et al. The effect of prophylactically administered n-acetylcysteine on clinical indicators for tissue oxygenation during hyperoxic ventilation in cardiac risk patients. Anaesthesist 1996; 45: 343-50 (German). 22. Landray MJ, Nuttall SL, Lydakis C, Martin U, Maxwell SR, Lip GY. Oxidative stress after thrombolysis. Lancet 1998; 352: 960. 3. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902. 5. Tardiolo G, Bramanti P, Mazzon E. Overview on the Effects of N-Acetylcysteine in Neurodegenerative Diseases. Molecules 2018; 23: 3305. 4. Moran AE, Forouzanfar MH, Roth GA, et al. The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation 2014; 129: 1493-501. 8. Eshraghi A, Talasaz AH, Salamzadeh J, et al. Evaluating the Effect of Intracoronary N-Acetylcysteine on Platelet Activation Markers After Primary Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction. Am J Ther 2016; 23: e44-51. 30. Horowitz JD, Antman EM, Lorell BH, Barry WH, Smith TW. Potentiation of the cardiovascular effects of nitroglycerin by N-acetylcysteine. Circulation 1983; 68: 1247-53. 20. Zweier JL, Flaherty JT, Weisfeldt ML. Direct measurement of free radical generation following reperfusion of ischemic myocardium. Proc Natl Acad Sci U S A 1987; 84: 1404-7. 7. Horowitz JD, Henry CA, Syrjanen ML, et al. Combined use of nitroglycerin and N-acetylcysteine in the management of unstable angina pectoris. Circulation 1988; 77: 787-94. 25. Brunet J, Boily MJ, Cordeau S, Des Rosiers C. Effects of N-acetylcysteine in the rat heart reperfused after low-flow ischemia: evidence for a direct scavenging of hydroxyl radicals and a nitric oxide-dependent increase in coronary flow. Free Radic Biol Med 1995; 19: 627-38. 31. Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987; 317: 799-804. 19. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121-35. 1. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J 2014; 35: 2950-9. 11. Pasupathy S, Tavella R, Grover S, et al. Early Use of N-acetylcysteine With Nitrate Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction Reduces Myocardial Infarct Size (the NACIAM Trial [N-acetylcysteine in Acute Myocardial Infarction]). Circulation 2017; 136: 894-903. 6. Abe M, Takiguchi Y, Ichimaru S, Tsuchiya K, Wada K. Comparison of the protective effect of N-acetylcysteine by different treatments on rat myocardial ischemia-reperfusion injury. J Pharmacol Sci 2008; 106: 571-7. 21. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 1977; 56: 786-94. 28. Anfossi G, Russo I, Massucco P, Mattiello L, Cavalot F, Trovati M. N-acetyl-L-cysteine exerts direct anti-aggregating effect on human platelets. Eur J Clin Invest 2001; 31: 452-61. 17. Bhatt DL. Percutaneous coronary intervention in 2018. JAMA 2018; 319: 2127-8. 16. Thiele H, Hildebrand L, Schirdewahn C, et al. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. J Am Coll Cardiol 2010; 55: 2201-9. 9. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006; 354: 2773-82. 29. Gibson KR, Winterburn TJ, Barrett F, Sharma S, MacRury SM, Megson IL. Therapeutic potential of N-acetylcysteine as an antiplatelet agent in patients with type-2 diabetes. Cardiovasc Diabetol 2011; 10: 43. 2. Weintraub WS, Daniels SR, Burke LE, et al; American Heart Association Advocacy Coordinating Committee; Council on Cardiovascular Disease in the Young; Council on the Kidney in Cardiovascular Disease; Council on Epidemiology and Prevention; Council on Cardiovascular Nursing; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Clinical Cardiology, and Stroke Council. Value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart Association. Circulation 2011; 124: 967-90. 13. Talasaz AH, Khalili H, Fahimi F, et al. Effects of N-acetylcysteine on the cardiac remodeling biomarkers and major adverse events following acute myocardial infarction: a randomized clinical trial. Am J Cardiovasc Drugs 2014; 14: 51-61. 18. Giannini F, Candilio L, Mitomo S, et al. A practical approach to the management of complications during percutaneous coronary intervention. JACC Cardiovasc Interv 2018; 11: 1797-810. 33. Kelly D, Cockerill G, Ng LL, et al. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J 2007; 28: 711-8. 15. Thayssen P, Lassen JF, Jensen SE, et al. Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial. Circ Cardiovasc Interv 2014; 7: 216-24. 32. Aihara K, Ikeda Y, Yagi S, Akaike M, Matsumoto T. Transforming Growth Factor-β1 as a Common Target Molecule for Development of Cardiovascular Diseases, Renal Insufficiency and Metabolic Syndrome. Cardiol Res Pract 2010; 2011: 175381. 22 23 24 25 26 27 28 29 (5) 2018; 23 31 10 32 11 33 12 13 14 (30) 1983; 68 15 16 17 18 19 1 2 3 4 6 7 8 9 20 21 |
References_xml | – ident: 17 doi: 10.1001/jama.2018.5281 – ident: 8 doi: 10.1097/MJT.0000000000000309 – ident: 27 doi: 10.1016/S0049-3848(03)00284-6 – ident: 22 doi: 10.1016/S0140-6736(05)61514-0 – ident: 20 doi: 10.1073/pnas.84.5.1404 – ident: 3 doi: 10.1056/NEJM198010163031601 – ident: 1 doi: 10.1093/eurheartj/ehu299 – ident: 14 – ident: 4 doi: 10.1161/CIRCULATIONAHA.113.004046 – ident: 6 doi: 10.1254/jphs.FP0071664 – ident: 25 doi: 10.1016/0891-5849(95)00077-B – ident: 29 doi: 10.1186/1475-2840-10-43 – volume: 23 start-page: 3305 issn: 1420-3049 year: 2018 ident: 5 publication-title: Molecules doi: 10.3390/molecules23123305 – ident: 11 doi: 10.1161/CIRCULATIONAHA.117.027575 – ident: 9 doi: 10.1056/NEJMoa054209 – ident: 28 doi: 10.1046/j.1365-2362.2001.00815.x – ident: 23 doi: 10.1016/S0002-9149(96)90580-9 – ident: 31 doi: 10.1056/NEJM198709243171304 – ident: 33 doi: 10.1093/eurheartj/ehm003 – ident: 19 doi: 10.1056/NEJMra071667 – ident: 21 doi: 10.1161/01.CIR.56.5.786 – volume: 68 start-page: 1247 issn: 0009-7322 year: 1983 ident: 30 publication-title: Circulation doi: 10.1161/01.CIR.68.6.1247 – ident: 2 doi: 10.1161/CIR.0b013e3182285a81 – ident: 7 doi: 10.1161/01.CIR.77.4.787 – ident: 18 doi: 10.1016/j.jcin.2018.05.052 – ident: 32 – ident: 13 doi: 10.1007/s40256-013-0048-x – ident: 15 doi: 10.1161/CIRCINTERVENTIONS.113.000653 – ident: 24 doi: 10.1253/circj.70.832 – ident: 16 doi: 10.1016/j.jacc.2009.08.091 – ident: 10 doi: 10.1007/s40256-017-0258-8 – ident: 26 doi: 10.1007/s001010050270 – ident: 12 doi: 10.1007/s40268-013-0025-5 |
SSID | ssj0041507 |
Score | 2.3219092 |
Snippet | The aim of this study was to evaluate the clinical efficacy of N-acetylcysteine (NAC) in the treatment of ST segment elevation myocardial infarction... The aim of this study was to evaluate the clinical efficacy of N-acetylcysteine (NAC) in the treatment of ST segment elevation myocardial infarction (STEMI).... |
SourceID | proquest crossref jstage |
SourceType | Aggregation Database Publisher |
StartPage | 142 |
SubjectTerms | Acetylcysteine Acute myocardial infarction All-cause mortality Congestive heart failure Heart attacks Major cardiovascular events Mortality Myocardial infarction Patients |
Subtitle | A Meta-Analysis and Systematic Review |
Title | The Clinical Efficacy of N-Acetylcysteine in the Treatment of ST Segment Elevation Myocardial Infarction |
URI | https://www.jstage.jst.go.jp/article/ihj/62/1/62_20-519/_article/-char/en https://www.proquest.com/docview/2486154773 |
Volume | 62 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | International Heart Journal, 2021/01/30, Vol.62(1), pp.142-147 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Nb9MwFLdgIMQF8SkKA1mCW-WR-CNNjtXUUU3rOJBKvVmx43StpgyN9DD-ep4_Em8UIeBitbZlWe_9_Pz88j4Q-shZnVV1kRIt6oxwzRTJWQ6NoLzJdKJq51W5OM_mS366EqvobuuiSzp1pH_8Nq7kf7gKfcBXGyX7D5wdFoUO-A38hRY4DO1f8_i4D22c2WQQtni7tQGQqTbdzaW2eZo3PjGI1TDLwa3cxqqUICnW7t_s0njT7HhxA5fbde1TcDRwCgbGbaPPezQh2nrY3fj2Zl26xw053fmgD0DfOroQmHZN5jt33e36gWByoNbe0H89cdcBXONR9lj7fvwMMJ66kNFbEpXxglDmC0IcmdjHqK-M1IvhjO7BzcvU1Kff2pP1whWj2Vxs4ZVPRBC8dxJqn3-RJ8uzM1nOVuV99IBOCmG9Pj-vBi8gbvVh9yYPuwwZbGHtT3HlOzrLwy2o7ev9u9spJOVT9CS8JPDUw-IZumfa5-jRIvhKvEAXgA7cowP36MBXDf4VHXjTYkAHHtBhJ30tcUAHHtCBIzpwRMdLtDyZlcdzEupqEM1E1hGtlNJZUyd5AQLd1JNGJI2wWdrr3FCtCkNBUVSg_KegsKpcJ7ypudaFyx9YCfYKHbRXrXmNcKpAu0k0UJYZe7YrXlGeV6yAh0jdKDVCH3rKyW8-fYq0z06grwT6SppIoO8IFZ6ow5xwpNycjMrUNn7uMGSjEkEIjNBhzwcZ0P5dwh5AU-eTCXvz5-G36HEE-CE66K535h1omZ1673DyExtHgnM |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Clinical+Efficacy+of+N-Acetylcysteine+in+the+Treatment+of+ST+Segment+Elevation+Myocardial+Infarction&rft.jtitle=International+heart+journal&rft.au=Shi-Jun%2C+Jiang&rft.au=Cheng-Hu%2C+Huang&rft.date=2021-01-30&rft.pub=Japan+Science+and+Technology+Agency&rft.issn=1349-2365&rft.eissn=1349-3299&rft.volume=62&rft.issue=1&rft.spage=142&rft_id=info:doi/10.1536%2Fihj.20-519&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1349-2365&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1349-2365&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1349-2365&client=summon |